ArticleDiscover oncology2026
Mean platelet volume-to-albumin ratio as a predictor of pathological complete response in HER2-positive breast cancer undergoing neoadjuvant chemotherapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the predictive value of the mean platelet volume–to–albumin (MPV/Alb) ratio for pathological complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treated with neoadjuvant chemotherapy (NACT).
methodsIn this retrospective single-center study, 139 consecutive patients with HER2-positive breast cancer who received dual anti-HER2 therapy combined with anthracycline- and taxane-based neoadjuvant chemotherapy between December 2022 and February 2025 were included. Clinicopathological variables, immuno-inflammatory parameters, and the MPV/Alb ratio were analyzed. Predictors of pCR were assessed using univariable and multivariable logistic regression. Discriminative performance and an optimal cut-off for MPV/Alb were determined by receiver operating characteristic (ROC) analysis.
resultsThe median age was 50 years (range, 26–79), and pCR was achieved in 54.7% of patients. On univariable analyses, estrogen receptor (ER) status, progesterone receptor (PR) status, and MPV/Alb were associated with pCR. In multivariable analysis, only MPV/Alb remained an independent predictor of pCR (p = 0.012; odds ratio [OR], 0.388; 95% confidence interval [CI], 0.185–0.813). ROC analysis identified an optimal MPV/Alb cutoff of 2.32 (AUC 0.626; 95% CI 0.535–0.720; p = 0.048), yielding 64.5% sensitivity and 58.7% specificity.
conclusionsThe MPV/Alb ratio may serve as an independent predictor of pCR in HER2-positive BC undergoing NACT. As a readily obtainable, low-cost composite derived from routine laboratory tests, MPV/Alb could aid risk stratification and treatment decision-making in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.